Multimodal deep learning model on interim [18F]FDG PET/CT for predicting primary treatment failure in diffuse large B-cell lymphoma
- PMID: 36029345
- DOI: 10.1007/s00330-022-09031-8
Multimodal deep learning model on interim [18F]FDG PET/CT for predicting primary treatment failure in diffuse large B-cell lymphoma
Abstract
Objectives: The prediction of primary treatment failure (PTF) is necessary for patients with diffuse large B-cell lymphoma (DLBCL) since it serves as a prominent means for improving front-line outcomes. Using interim 18F-fluoro-2-deoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) imaging data, we aimed to construct multimodal deep learning (MDL) models to predict possible PTF in low-risk DLBCL.
Methods: Initially, 205 DLBCL patients undergoing interim [18F]FDG PET/CT scans and the front-line standard of care were included in the primary dataset for model development. Then, 44 other patients were included in the external dataset for generalization evaluation. Based on the powerful backbone of the Conv-LSTM network, we incorporated five different multimodal fusion strategies (pixel intermixing, separate channel, separate branch, quantitative weighting, and hybrid learning) to make full use of PET/CT features and built five corresponding MDL models. Moreover, we found the best model, that is, the hybrid learning model, and optimized it by integrating the contrastive training objective to further improve its prediction performance.
Results: The final model with contrastive objective optimization, named the contrastive hybrid learning model, performed best, with an accuracy of 91.22% and an area under the receiver operating characteristic curve (AUC) of 0.926, in the primary dataset. In the external dataset, its accuracy and AUC remained at 88.64% and 0.925, respectively, indicating its good generalization ability.
Conclusions: The proposed model achieved good performance, validated the predictive value of interim PET/CT, and holds promise for directing individualized clinical treatment.
Key points: • The proposed multimodal models achieved accurate prediction of primary treatment failure in DLBCL patients. • Using an appropriate feature-level fusion strategy can make the same class close to each other regardless of the modal heterogeneity of the data source domain and positively impact the prediction performance. • Deep learning validated the predictive value of interim PET/CT in a way that exceeded human capabilities.
Keywords: Deep learning; Lymphoma; Positron emission tomography/computed tomography; Treatment failure.
© 2022. The Author(s), under exclusive licence to European Society of Radiology.
Similar articles
-
Prognostic analysis of interim 18F-FDG PET/CT in patients with diffuse large B cell lymphoma after one cycle versus two cycles of chemotherapy.Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):478-488. doi: 10.1007/s00259-018-4198-6. Epub 2018 Oct 31. Eur J Nucl Med Mol Imaging. 2019. PMID: 30382301 Free PMC article.
-
Different predictive values of interim 18F-FDG PET/CT in germinal center like and non-germinal center like diffuse large B-cell lymphoma.Ann Nucl Med. 2017 Jan;31(1):1-11. doi: 10.1007/s12149-016-1123-6. Epub 2016 Sep 15. Ann Nucl Med. 2017. PMID: 27627889
-
Texture Analysis Improves the Value of Pretreatment 18F-FDG PET/CT in Predicting Interim Response of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.Contrast Media Mol Imaging. 2020 Aug 21;2020:2981585. doi: 10.1155/2020/2981585. eCollection 2020. Contrast Media Mol Imaging. 2020. PMID: 32922221 Free PMC article.
-
Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis.Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):65-79. doi: 10.1007/s00259-018-4103-3. Epub 2018 Aug 23. Eur J Nucl Med Mol Imaging. 2019. PMID: 30141066 Free PMC article.
-
Clinical scoring systems, molecular subtypes and baseline [18F]FDG PET/CT image analysis for prognosis of diffuse large B-cell lymphoma.Cancer Imaging. 2024 Dec 18;24(1):168. doi: 10.1186/s40644-024-00810-8. Cancer Imaging. 2024. PMID: 39696503 Free PMC article. Review.
Cited by
-
Enhancing Lymphoma Diagnosis, Treatment, and Follow-Up Using 18F-FDG PET/CT Imaging: Contribution of Artificial Intelligence and Radiomics Analysis.Cancers (Basel). 2024 Oct 17;16(20):3511. doi: 10.3390/cancers16203511. Cancers (Basel). 2024. PMID: 39456604 Free PMC article. Review.
-
Multimodal deep learning approaches for precision oncology: a comprehensive review.Brief Bioinform. 2024 Nov 22;26(1):bbae699. doi: 10.1093/bib/bbae699. Brief Bioinform. 2024. PMID: 39757116 Free PMC article. Review.
-
A Systematic Review of the Applications of Deep Learning for the Interpretation of Positron Emission Tomography Images of Patients with Lymphoma.Cancers (Basel). 2024 Dec 29;17(1):69. doi: 10.3390/cancers17010069. Cancers (Basel). 2024. PMID: 39796698 Free PMC article. Review.
-
A Comprehensive Review on RNA Subcellular Localization Prediction.ArXiv [Preprint]. 2025 Apr 24:arXiv:2504.17162v1. ArXiv. 2025. PMID: 40313658 Free PMC article. Preprint.
-
PET/CT based cross-modal deep learning signature to predict occult nodal metastasis in lung cancer.Nat Commun. 2023 Nov 18;14(1):7513. doi: 10.1038/s41467-023-42811-4. Nat Commun. 2023. PMID: 37980411 Free PMC article.
References
-
- Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249 - DOI
-
- Feugier P, Van Hoof A, Sebban C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 23:4117–4126 - DOI
-
- Crump M, Neelapu SS, Farooq U et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800–1808 - DOI
-
- Gisselbrecht C, Neste EVD (2018) How I manage patients with relapsed/refractory diffuse large B cell lymphoma. Br J Haematol 182:633–643 - DOI
-
- Locke FL, Ghobadi A, Jacobson CA et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 20(1):31–42 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources